Is CADX a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

511 people get CADX articles and Market Currents by email alert.

Get email alerts on CADX »

HEADLINES:

Cadence's Management Presents at UBS Global Healthcare Conference (Transcript)
Tue, May 21
Cadence Pharmaceuticals' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)
Thu, May 16
SmithOnStocks Opines On Recent Biotech News
Smith On Stocks • Mon, May 13 • 8 Comments
Cadence Pharmaceuticals To Present At Three Investment Conferences During The Month Of May 2013

PR Newswire (May 8, 2013)
Cadence Pharmaceuticals: Ofirmev Launch Is Strong; Resolution Of Patent Issues Could Be Soon
Smith On Stocks • Mon, May 6
Cadence Pharmaceuticals, Inc. CEO Discuses Q1 2013 Results - Earnings Call Transcript
Thu, May 2 • 2 Comments
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results

PR Newswire (May 2, 2013)
Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss First Quarter 2013 Financial Results On May 2, 2013

PR Newswire (Apr 25, 2013)
Cadence Is Tiring Out And Generic Risks Suggest Taking Profit
PropThink • Thu, Mar 28 • 6 Comments
Cadence Pharmaceuticals Appoints Stephen L. Newman, M.D., to its Board of Directors

PR Newswire (Mar 14, 2013)
Cadence Pharmaceuticals Announces the Availability of OFIRMEV® (acetaminophen) Injection through the VA National Formulary

PR Newswire (Mar 12, 2013)
Cadence: Potential Near-Term Catalyst For The Stock
Smith On Stocks • Mon, Mar 11 • 9 Comments
Cadence Pharmaceuticals CEO Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Mar 7 • 1 Comment
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results

PR Newswire (Mar 7, 2013)
Cadence Pharmaceuticals Announces Strategic Plan to Secure Long-Term Manufacture and Supply of OFIRMEV® (acetaminophen) Injection

PR Newswire (Mar 6, 2013)
Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On March 7, 2013

PR Newswire (Feb 28, 2013)
Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013

PR Newswire (Feb 26, 2013)
Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The Leerink Swann Global Healthcare Conference In New York City On February 13, 2013

PR Newswire (Feb 6, 2013)
Cadence Management Guides To A Near Doubling Of Ofirmev Sales In 2013
Smith On Stocks • Wed, Jan 23 • 1 Comment
Cadence Pharmaceuticals Estimates Fourth Quarter 2012 Net Product Revenue and Provides Full Year 2013 Revenue Guidance

PR Newswire (Jan 23, 2013)

To learn more about Seeking Alpha Pro, click here.

Cadence Pharmaceuticals: Ofirmev Launch Is Strong; Resolution Of Patent Issues Could Be Soon
Smith On Stocks • Mon, May 6
Cadence Is Tiring Out And Generic Risks Suggest Taking Profit
PropThink • Thu, Mar 28 • 6 Comments
Cadence: Potential Near-Term Catalyst For The Stock
Smith On Stocks • Mon, Mar 11 • 9 Comments
Cadence Management Guides To A Near Doubling Of Ofirmev Sales In 2013
Smith On Stocks • Wed, Jan 23 • 1 Comment
Cadence Pharmaceuticals: Sentiment Is Shifting From Bearish To Bullish
Smith On Stocks • Fri, Dec 21, 2012 • 3 Comments
CADX To Receive $14.5M Or $0.15/Share In Non-Dilutive Funds
PropThink • Wed, Dec 12, 2012
Cadence Pharmaceuticals Investor/Analyst Day Highlights Strong Ofirmev Growth Trends
PropThink • Thu, Dec 6, 2012
Cadence Pharmaceutical's Patent Settlement Bolsters My Buy Rating
Smith On Stocks • Wed, Nov 28, 2012 • 3 Comments
Strong August Results Bolster Confidence In Success Of Cadence Pharma's Ofirmev Launch
Smith On Stocks • Thu, Sep 20, 2012 • 3 Comments
2 Positive News Items Help The Cadence Pharmaceuticals Investment Thesis
Smith On Stocks • Mon, Aug 27, 2012
Cadence Pharmaceuticals' Ofirmev Launch Has Gained Traction: Buy
Smith On Stocks • Tue, Aug 7, 2012 • 3 Comments
Cadence Pharmaceuticals: Ofirmev Sales Could Provide Upside Surprise In 2Q
Smith On Stocks • Fri, Jun 22, 2012 • 8 Comments
Cadence Pharmaceuticals: Ofirmev Sales Could Produce Upside Surprises In Coming Quarters
Smith On Stocks • Fri, Jun 1, 2012 • 5 Comments
Cadence: Not Altering Sales Projections Or Rating In Aftermath Of Product Recall
Smith On Stocks • Wed, Feb 8, 2012
Cadence's Ofirmev Launch Is Gaining Traction
Smith On Stocks • Wed, Jan 25, 2012 • 6 Comments
Cadence Pharmaceuticals: Good For Patients, Bad For Investors
ScriptVolume • Mon, Dec 26, 2011 • 2 Comments
Cadence: Not Unduly Concerned About ANDA Filing Against Ofirmev
Smith On Stocks • Tue, Jul 5, 2011 • 5 Comments
Cadence Pharmaceuticals: Encouraging Formulary Acceptance for Ofirmev
Smith On Stocks • Fri, May 6, 2011 • 6 Comments
3 Ways to Participate in Cadence Pharmaceuticals' Breakout
Sebastien Buttet • Sun, Apr 10, 2011 • 1 Comment
Cadence Pharmaceuticals Needs Fast-Paced Ofirmev Launch to Build Confidence
EP Vantage • Mon, Feb 14, 2011 • 6 Comments

SmithOnStocks Opines On Recent Biotech News
Smith On Stocks • Mon, May 13 • 8 Comments
8 Stocks Under $5 On Winning Streaks
Kapitall • Tue, Dec 18, 2012
5 Highly Liquid Small Cap Stocks Projected For Strong Growth
ZetaKap • Tue, Oct 9, 2012 • 2 Comments
6 Liquid Small-Cap Healthcare Stocks Projected For Strong Growth
ZetaKap • Thu, Aug 30, 2012
7 Outperforming Healthcare Stocks Being Sold By Hedge Fund Managers
Kapitall • Thu, Aug 9, 2012 • 1 Comment
6 Analyst Backed Small Cap Biotech Stocks With Plenty Of Cash Cash
ZetaKap • Fri, Aug 3, 2012
4 Stocks Expected To Grow At Least 23% That Should Be Considered At Current Levels
Matt Schilling • Mon, Jul 16, 2012 • 5 Comments
7 Fast Growing Small Cap Biotech Stocks With Analyst Confidence
ZetaKap • Fri, Jul 6, 2012
Survey Of Surgeons Indicates Strong Launch For Exparel
LifeSci Advisors • Thu, Jul 5, 2012 • 2 Comments
8 Biotechnology Stocks With Good Liquidity That Analysts Rate As Buy
ZetaKap • Fri, May 25, 2012
6 High-Growth Biotechnology Stocks With Great Liquidity
ZetaKap • Tue, May 15, 2012
A.P. Pharma: Unusual Potential For A Small Company
Smith On Stocks • Fri, Apr 27, 2012 • 1 Comment
Transcept: The Intermezzo Launch Is Underway
Smith On Stocks • Tue, Apr 24, 2012 • 2 Comments
18 Stocks Under $5 Being Bought Up By Hedge Funds
Kapitall • Mon, Apr 2, 2012 • 2 Comments
MAP's Levadex Will Likely Be Approved March 26
Smith On Stocks • Tue, Mar 13, 2012 • 14 Comments
Jakafi Launch: Survey Reveals Upside To Stock
LifeSci Advisors • Tue, Jan 24, 2012 • 1 Comment
Transcept's Intermezzo Has Significant Long-Term Potential, But What About 2012?
Smith On Stocks • Tue, Jan 24, 2012 • 11 Comments
5 Specialty Pharma Stocks To Avoid
Insider Monkey • Wed, Jan 18, 2012 • 2 Comments
Short-Sellers Expect These 14 Biotechs To Outperform
Kapitall • Thu, Jan 5, 2012
20 Biotech Stocks That Hedge Funds Are Selling
Kapitall • Sun, Dec 11, 2011 • 1 Comment

Cadence's Management Presents at UBS Global Healthcare Conference (Transcript)
Tue, May 21
Cadence Pharmaceuticals' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)
Thu, May 16
Cadence Pharmaceuticals, Inc. CEO Discuses Q1 2013 Results - Earnings Call Transcript
Thu, May 2 • 2 Comments
Cadence Pharmaceuticals CEO Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Mar 7 • 1 Comment
Cadence Pharmaceuticals' CEO Hosts Analyst and Investor Day Conference (Transcript)
Thu, Dec 6, 2012
Cadence Pharmaceuticals' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Mon, Nov 5, 2012
Cadence Pharmaceuticals' Management Presents at the 2012 Wedbush PACGROW Life Sciences Management Access Conference (Transcript)
Tue, Aug 14, 2012
Cadence Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript
Fri, Aug 3, 2012
Cadence CEO Discusses Q3 2010 Results - Earnings Call Transcript
Fri, Nov 5, 2010
Cadence Pharmaceuticals Inc. Q2 2010 Earnings Call Transcript
Thu, Aug 5, 2010
Cadence Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript
Thu, May 6, 2010
Cadence Pharmaceuticals, Inc., Q4 2008 Earnings Call Transcript
Thu, Mar 12, 2009
Cadence Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
Wed, Nov 19, 2008
Cadence Pharmaceuticals, Inc. Q2 2008 Earnings Call Transcript
Tue, Sep 2, 2008
Cadence Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript
Mon, May 26, 2008
Cadence Pharmaceuticals, Incorporated Q4 2007 Earnings Call Transcript
Thu, Apr 17, 2008
Cadence Pharmaceuticals Q3 2007 Earnings Call Transcript
Thu, Nov 15, 2007

Cadence Pharmaceuticals To Present At Three Investment Conferences During The Month Of May 2013

PR Newswire (May 8, 2013)
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results

PR Newswire (May 2, 2013)
Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss First Quarter 2013 Financial Results On May 2, 2013

PR Newswire (Apr 25, 2013)
Cadence Pharmaceuticals Appoints Stephen L. Newman, M.D., to its Board of Directors

PR Newswire (Mar 14, 2013)
Cadence Pharmaceuticals Announces the Availability of OFIRMEV® (acetaminophen) Injection through the VA National Formulary

PR Newswire (Mar 12, 2013)
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results

PR Newswire (Mar 7, 2013)
Cadence Pharmaceuticals Announces Strategic Plan to Secure Long-Term Manufacture and Supply of OFIRMEV® (acetaminophen) Injection

PR Newswire (Mar 6, 2013)
Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On March 7, 2013

PR Newswire (Feb 28, 2013)
Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013

PR Newswire (Feb 26, 2013)
Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The Leerink Swann Global Healthcare Conference In New York City On February 13, 2013

PR Newswire (Feb 6, 2013)
Cadence Pharmaceuticals Estimates Fourth Quarter 2012 Net Product Revenue and Provides Full Year 2013 Revenue Guidance

PR Newswire (Jan 23, 2013)
Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.

PR Newswire (Dec 12, 2012)
Cadence Pharmaceuticals to Host Analyst and Investor Day

PR Newswire (Nov 28, 2012)
Cadence Pharmaceuticals Announces Settlement of OFIRMEV® (Acetaminophen) Injection Patent Litigation with Perrigo Company

PR Newswire (Nov 28, 2012)
Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The Piper Jaffray 24th Annual Healthcare Conference In New York City On November 28, 2012

PR Newswire (Nov 21, 2012)
Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results

PR Newswire (Nov 5, 2012)
Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2012 Financial Results On November 5, 2012

PR Newswire (Oct 29, 2012)
Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2012 In Boston On September 5, 2012

PR Newswire (Aug 29, 2012)
Health Care Sector Wrap

at Fox Business (Aug 23, 2012)
Health Care Sector Wrap

at Fox Business (Aug 23, 2012)

CADX vs. ETF Alternatives

Company Description

Currently, there's no company description for CADX.

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 3, 6:52 AM Cadence (CADX): Q1 EPS of -$0.02 beats by $0.13. Revenue of $23.6M beats by $3.75M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, March 7, 11:57 AM Cadence Pharmaceutical (CADX +2%) moves up after beating Q4 estimates across the board. Total revenue rose over 180% Y/Y, driven by higher licensing revenue driven by it's data license agreement with Terumo Corporation. Terumo intends to seek regulatory approval in Japan for the same intravenous formulation of acetaminophen as CADX's Ofirmev. 1 Comment [Healthcare, On the Move, Earnings]
Thursday, March 7, 7:41 AM Cadence Pharmaceuticals (CADX): Q4 EPS of -$0.15 beats by $0.01. Revenue of $17.2M beats by $0.5M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Friday, December 14, 2012, 5:39 PM After-hours top gainers, as of 5:15 p.m.: ETH +10%. TVL +7%. AVG +5%. ARQL +5%. EZPW +4%.
After-hours top losers: CADX -6%. AVNR -5%. ITG -5%. BEBE -5%. ISIS -4%. 1 Comment [On the Move]
Wednesday, December 12, 2012, 12:47 PM As a condition of Medicines Company's (MDCO +1.9%) acquisition of Incline Therapeutics, Cadence Pharmaceuticals (CADX +4.9%) has agreed to terminate its exclusive option to acquire Incline. Upon MDCO's closing of the deal, CADX will receive around $13M in termination fees and roughly $1.5M for its Incline stake as well as a pro-rated share of future milestone payments. Comment! [Healthcare, On the Move, M&A]
Wednesday, November 28, 2012, 10:01 AM Cadence Pharmaceuticals (CADX +3.4%) and Perrigo (PRGO -1.3%) settle a lawsuit over Cadence's Ofirmev injection for reducing fever and pain. Under the deal, Perrigo has the first right of refusal to market any generic version of Ofirmev in the U.S. should Cadence decide to authorize such a version. Perrigo will also be allowed to launch a copycat drug in 2020. (PR) Comment! [Healthcare]
Tuesday, February 7, 2012, 1:54 PM Cadence Pharmaceuticals (CADX +0.1%) voluntarily recalls some of its Ofirmev pain reliever injection vials after an unidentified particle was found in one of the lot's vials during routine stability testing. Comment! [Healthcare]
Tuesday, November 15, 2011, 11:34 AM Cadence Pharmaceuticals (CADX -4.5%) trades down after pricing its 19M share offering at $3.75 per share, a 5.5% discount to Monday's closing price. Comment! [Healthcare, On the Move]
Tuesday, November 15, 2011, 9:05 AM Premarket gainers: CIM +7%. MX +7%. DKS +6%. RVBD +3%.
Losers: GERN -20%. HAFC -15%. LDK -8%. CADX -8%. PVR -6%. NBG -5%. FRO -5%. ING -5%. ATVI -5%. URBN -4%. KOG -4%. CS -4%. TTWO -4%. LOGI -3%. MT -3%. Comment! [On the Move]
Monday, November 14, 2011, 10:50 AM Cadence Pharmaceuticals (CADX -15.8%) takes a hit after announcing plans for a $75M secondary stock offering. The company plans to use the majority of the funds for research and development of its injectable acetaminophen drug Ofirmev. Comment! [Healthcare, On the Move]
Monday, November 14, 2011, 10:05 AM Cadence Pharmaceuticals (CADX) trades 13.1% lower after announcing a plan to sell $75M of common stock on a market cap sitting south of $300M. Undeterred by the firm's new public offering of shares, Colins Stewart initiates coverage with a Buy rating and a lofty $7 price target. 1 Comment [On the Move, Healthcare]
Monday, April 19, 2010, 10:22 AM Shares of Cadence Pharmaceuticals (CADX +12.0%) jump on news that the company will resubmit its market application for U.S. approval of its acetaminophen intravenous formulation within 30 days. (PR) Comment!
Thursday, February 11, 2010, 9:00 AM Premarket gainers: AZC +24%. LF +18%. SOL +12%. AYE +11%. JASO +8%. ATVI +6%. CPA +4%.
Losers: ELON -15%. SWIR -15%. CADX -13%. HOS -12%. BSX -8%. ALU -8%. FE -4%. Comment!
Friday, November 13, 2009, 9:00 AM Premarket gainers: TSTC +31%. RINO +18%. LXRX +17%. ANF +7%. MDSO +7%. JCP +5%. PLA +4%.
Losers: LBTYA -9%. LKFN -7%. CADX -6%. TCLP -5%. JWN -4%. Comment!
Friday, March 13, 2009, 6:39 PM Healthcare was the strongest sector Friday, up 2.44% overall. Biggest gainers: CADX +19.2%; DNDN +18.2%; NPSP+17.5%; EVVV +13.9%; MYL +12.8%; MRK +12.7%. The only double-digit loser on the day: PGNX -16.1%. Comment!

ZetaKap
5 Highly Liquid Small Cap Stocks Projected For Strong Growth http://bit.ly/T29R1J $CADX $DXCM $ELOS $LMNX $TPLM @ZetaKap
10/9/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
6 Liquid Small-Cap Healthcare Stocks Projected For Strong Growth http://bit.ly/PufuoU $ACOR $AVNR $CADX $MDCO $NXTM $QLTI @ZetaKap
8/30/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
6 Analyst Backed Small Cap Biotech Stocks With Plenty Of Cash Cash http://bit.ly/Nr2Ftd $ACOR $CADX $IMGN $QLTI $VPHM $VVUS @ZetaKap
8/3/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
7 Fast Growing Small Cap Biotech Stocks With Analyst Confidence http://bit.ly/Odu3LZ $EXAS $MACK $NKTR $THLD $CADX $SNTS $ACOR @ZetaKap
7/6/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
8 Biotechnology Stocks With Good Liquidity That Analysts Rate As Buy http://bit.ly/MxU9KJ $DYAX $CADX $BMRN $CYTX $CVM $AMGN $ALXN $CELG
5/25/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
$$ 6 High-Growth Biotechnology Stocks With Great Liquidity http://bit.ly/JRnwbm $ACOR $ALXN $ANIK $BMRN $CADX $CRTX @ZetaKap
5/15/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
http://bit.ly/KW1sxj Earnings after hours: $AIG $BEBE, $BODY $CADX $CNQ $CF $DOLE $EXEL $ISTA $MDLZ $KOG $LNKD $SD $SPRD $SQNM $ZAG
5/3/12
Reply (3)

• !Report Abuse
View all 3 replies
cn_habs: NES is up 12% in AH yet missed earnings...
5/3/12
• !Report Abuse
freefdawatchlist: AIG is down 2%, LNKD is up
5/3/12
• !Report Abuse
Add a reply...

140 characters

I4invest
(CADX). My wife who is a nurse told me, their intravenous acetaminophen device. is the topic of conversation among Doctors on the job
4/1/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

freefdawatchlist
http://bit.ly/KW1sxj Earnings after hours: $AIG $BEBE, $BODY $CADX $CNQ $CF $DOLE $EXEL $ISTA $MDLZ $KOG $LNKD $SD $SPRD $SQNM $ZAG
5/3/12
Reply (3)

• !Report Abuse
View all 3 replies
cn_habs: NES is up 12% in AH yet missed earnings...
5/3/12
• !Report Abuse
freefdawatchlist: AIG is down 2%, LNKD is up
5/3/12
• !Report Abuse
Add a reply...

140 characters

CADX Cadence Pharmaceuticals, Inc.

CADX

Cadence Pharmaceuticals, Inc.